John Crowley, Amicus CEO
Amicus spins out gene therapy unit in SPAC deal as it pivots efforts toward Pompe disease program
A rare disease biotech out of Philadelphia is spinning out its gene therapy unit to reverse merge with a blue-chip SPAC.
Amicus Therapeutics will send …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
